Maze Therapeutics Inc(MAZE) - 2025 Q4 - Annual Results

Exhibit 99.1 Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, ...